CRISPR THERAPEUTICS AG's ticker is CRSP and the CUSIP is H17182108. A total of 258 filers reported holding CRISPR THERAPEUTICS AG in Q1 2020. The put-call ratio across all filers is 0.73 and the average weighting 0.4%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q4 2022 | $488,003 | -37.8% | 12,005 | 0.0% | 0.32% | -44.2% |
| Q3 2022 | $785,000 | +7.5% | 12,005 | -0.0% | 0.56% | +17.7% |
| Q2 2022 | $730,000 | -29.5% | 12,008 | +29.7% | 0.48% | -8.4% |
| Q3 2021 | $1,036,000 | -31.3% | 9,256 | -0.7% | 0.52% | -32.0% |
| Q2 2021 | $1,509,000 | +82.2% | 9,324 | +37.1% | 0.77% | +223.9% |
| Q1 2021 | $828,000 | +55.3% | 6,800 | +95.4% | 0.24% | -22.5% |
| Q4 2020 | $533,000 | -31.3% | 3,480 | -62.5% | 0.31% | -47.2% |
| Q3 2020 | $776,000 | +23.6% | 9,283 | +8.5% | 0.58% | +8.0% |
| Q2 2020 | $628,000 | +72.1% | 8,552 | -0.5% | 0.54% | +23.1% |
| Q1 2020 | $365,000 | -31.8% | 8,595 | -2.2% | 0.44% | -7.6% |
| Q4 2019 | $535,000 | +19.7% | 8,789 | -43.8% | 0.47% | +18.0% |
| Q4 2018 | $447,000 | -43.3% | 15,633 | -12.0% | 0.40% | -21.8% |
| Q3 2018 | $788,000 | – | 17,765 | – | 0.51% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Gilfoyle Management LLC | 150 | $6,376 | 12.96% |
| Versant Venture Management, LLC | 498,558 | $22,629,548 | 12.03% |
| NEA Management Company, LLC | 1,587,854 | $72,072,693 | 5.57% |
| ARK Investment Management | 7,163,118 | $325,133,913 | 2.49% |
| Nikko Asset Management Americas, Inc. | 3,465,470 | $157,263,029 | 1.88% |
| Integral Health Asset Management, LLC | 275,000 | $12,482,250 | 1.73% |
| Merlin Capital, Inc | 9,092 | $412,686 | 1.54% |
| Del-Sette Capital Management, LLC | 33,977 | $1,542,216 | 1.52% |
| Green Alpha Advisors, LLC | 34,880 | $1,583,203 | 1.22% |
| Ikarian Capital, LLC | 2,039 | $9,255,021 | 1.11% |